Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Master's Award: Canada Graduate Scholarships

University of Toronto

$17,500.00

Evaluating the Use of Circulating Tumor DNA from Cerebrospinal Fluid to Detect Minimal Residual Disease in Atypical Teratoid Rhabdoid Tumor

EF 2023-24

Résumé
Atypical Teratoid Rhabdoid Tumors (ATRTs) are highly fatal pediatric brain cancers. Treatment involves a combination of surgery, chemotherapy, and radiation which cures very few patients, and leaves survivors with life-long toxicity, including cognitive damage from radiation. To address therapeutic gaps, SickKids developed a standard of care (SKSOC) regimen for ATRTs that avoids radiation. However, therapeutic progress is limited by lack of methods to detect minimal residual disease (MRD) or monitor treatment response. Next generation sequencing of circulating tumor DNA (ctDNA) has become a promising tool for tumor surveillance, measuring treatment efficacy, and discovery of new targetable genetic abnormalities. My project will evaluate the efficacy of the SKSOC and develop a CSF ctDNA tool to assess whether MRD correlates with patient outcomes. Data will be collected from 27 patients treated by the SKSOC. Comprehensive analyses will identify patient and treatment related prognostic factors. Outcomes will be compared to the recent ACNS0333 clinical trial and a larger cohort from the Rare Brain Tumor Consortium registry to assess the safety and feasibility of SKSOC. To develop a targeted sequencing panel for a ctDNA assay, we will optimize extraction and library preparation of ctDNA from CSF of SKSOC patients for whole genome sequencing analyses. Data will be examined for genetic abnormalities typically associated with ATRTs. Results will be correlated with survival data to evaluate whether MRD detection from CSF corresponds with disease relapse or survival outcomes. This integrative analysis will inform whether MRD detection can stratify patients who can be spared from radiation and help tailor ATRT therapy to reduce excessive treatment and toxicity in young patients.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
506408
Name
Leung Lydia K
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Evaluating the Use of Circulating Tumor DNA from Cerebrospinal Fluid to Detect Minimal Residual Disease in Atypical Teratoid Rhabdoid Tumor
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Atypical Teratoid Rhabdoid Tumor; Brain Tumor; Circulating Tumor Dna; Disease Prognosticators; Liquid Biopsy; Pathology; Pediatrics; Survival; Toxicity; Treatment
Abstract
Atypical Teratoid Rhabdoid Tumors (ATRTs) are highly fatal pediatric brain cancers. Treatment involves a combination of surgery, chemotherapy, and radiation which cures very few patients, and leaves survivors with life-long toxicity, including cognitive damage from radiation. To address therapeutic gaps, SickKids developed a standard of care (SKSOC) regimen for ATRTs that avoids radiation. However, therapeutic progress is limited by lack of methods to detect minimal residual disease (MRD) or monitor treatment response. Next generation sequencing of circulating tumor DNA (ctDNA) has become a promising tool for tumor surveillance, measuring treatment efficacy, and discovery of new targetable genetic abnormalities. My project will evaluate the efficacy of the SKSOC and develop a CSF ctDNA tool to assess whether MRD correlates with patient outcomes. Data will be collected from 27 patients treated by the SKSOC. Comprehensive analyses will identify patient and treatment related prognostic factors. Outcomes will be compared to the recent ACNS0333 clinical trial and a larger cohort from the Rare Brain Tumor Consortium registry to assess the safety and feasibility of SKSOC. To develop a targeted sequencing panel for a ctDNA assay, we will optimize extraction and library preparation of ctDNA from CSF of SKSOC patients for whole genome sequencing analyses. Data will be examined for genetic abnormalities typically associated with ATRTs. Results will be correlated with survival data to evaluate whether MRD detection from CSF corresponds with disease relapse or survival outcomes. This integrative analysis will inform whether MRD detection can stratify patients who can be spared from radiation and help tailor ATRT therapy to reduce excessive treatment and toxicity in young patients.
Competitiondate
202312
Approvedterm2
1 yr 0 mth
Pinamesdelim
Leung, Lydia K
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~